Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aravive Inc (ARAV)

Aravive Inc (ARAV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,950
  • Shares Outstanding, K 73,563
  • Annual Sales, $ 9,140 K
  • Annual Income, $ -76,320 K
  • 60-Month Beta 2.19
  • Price/Sales 0.50
  • Price/Cash Flow N/A
  • Price/Book 1.73
Trade ARAV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings $-0.10 on 11/09/23
  • Next Earnings Date 08/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0400 +0.25%
on 01/23/24
0.1292 -68.96%
on 01/02/24
-0.0882 (-68.75%)
since 12/26/23
3-Month
0.0400 +0.25%
on 01/23/24
0.1820 -77.97%
on 11/30/23
-0.0969 (-70.73%)
since 10/26/23
52-Week
0.0400 +0.25%
on 01/23/24
2.4600 -98.37%
on 03/21/23
-1.6699 (-97.65%)
since 01/26/23

Most Recent Stories

More News
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

ONC.TO : 1.44 (+1.41%)
ONCY : 1.0400 (unch)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 1, 2022 – USA News Group  –  A series of new Fast Track designations have been handed out by the United States...

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
RHHBY : 40.7600 (+3.03%)
ARAV : 0.0401 (-13.39%)
CRBU : 2.49 (+2.05%)
KTRA : 0.2448 (+12.71%)
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b...

ARAV : 0.0401 (-13.39%)
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia...

ARAV : 0.0401 (-13.39%)
Aravive Appoints Rudy Howard as Chief Financial Officer

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted...

ARAV : 0.0401 (-13.39%)
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class...

ARAV : 0.0401 (-13.39%)
Aravive to Participate in H.C. Wainwright Global Investment Conference

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat...

ARAV : 0.0401 (-13.39%)
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting

HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...

ARAV : 0.0401 (-13.39%)
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to...

ARAV : 0.0401 (-13.39%)

Business Summary

Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States.

See More

Key Turning Points

3rd Resistance Point 0.0499
2nd Resistance Point 0.0480
1st Resistance Point 0.0440
Last Price 0.0401
1st Support Level 0.0381
2nd Support Level 0.0362
3rd Support Level 0.0322

See More

52-Week High 2.4600
Fibonacci 61.8% 1.5356
Fibonacci 50% 1.2500
Fibonacci 38.2% 0.9644
Last Price 0.0401
52-Week Low 0.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar